Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

141
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
141
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

108
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
108
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

89
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
89
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

147
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
147

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antioxidants as Therapeutic Tools in the Management of COPD: A Systematic Review with Meta-Analysis.

Antioxidants (Basel, Switzerland)·2026
Same author

Hydrodynamic Delivery of IL-10 Gene for Local Immunomodulation in Human Crohn's Disease Tissue: A Proof-of-Concept Study.

Pharmaceutics·2026
Same author

Genetic Variants Associated with Fluoropyrimidine-Induced Toxicity in Real-World Patients After Pre-Emptive <i>DPYD</i> Pharmacogenetic Testing.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Corrigendum to "Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort" [Curr. Res. Pharmacol. Drug Discov. 9 (2025) 100230].

Current research in pharmacology and drug discovery·2026
Same author

Update on pharmacogenetics in pediatrics.

Anales de pediatria·2026
Same author

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.

BMC cancer·2025

Related Experiment Video

Updated: Mar 27, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Clinical implementation of pharmacogenetics.

Xandra García-González, Teresa Cabaleiro, María José Herrero

    Drug Metabolism and Personalized Therapy
    |January 12, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Pharmacogenetic research advances cancer treatment and transplant care, but clinical application lags. This review explores challenges and the status of pharmacogenetic testing implementation.

    More Related Videos

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.8K
    Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
    08:27

    Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

    Published on: July 27, 2021

    5.0K

    Related Experiment Videos

    Last Updated: Mar 27, 2026

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
    08:46

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

    Published on: December 9, 2015

    11.3K
    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.8K
    Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
    08:27

    Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

    Published on: July 27, 2021

    5.0K

    Area of Science:

    • Pharmacogenetics and Pharmacogenomics
    • Clinical Pharmacology
    • Translational Medicine

    Background:

    • Pharmacogenetic research has advanced significantly but clinical implementation remains slow.
    • Translating pharmacogenetic findings into routine clinical practice presents challenges.
    • The VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics Society highlighted these issues.

    Purpose of the Study:

    • To discuss the current state of clinical implementation of pharmacogenetics.
    • To review advances in pharmacogenomics for personalized cancer therapy.
    • To examine pharmacogenetics in transplant patient management and identify barriers to clinical application.

    Main Methods:

    • Review of lectures from the Clinical Implementation of Pharmacogenetics Symposium.
    • Focus on pharmacogenomics in oncology and immunosuppressive therapy for transplant patients.
    • Analysis of needs, barriers, and the status of pharmacogenetic testing in Spain.

    Main Results:

    • Pharmacogenomics offers potential for individualizing cancer treatments.
    • Pharmacogenetics influences pharmacodynamics and clinical outcomes in transplant patients on immunosuppressants.
    • Significant barriers hinder the widespread clinical application of pharmacogenetics.
    • The status of pharmacogenetic testing in Spain was evaluated.

    Conclusions:

    • Accelerating the clinical integration of pharmacogenetics is crucial for personalized medicine.
    • Addressing identified needs and barriers is essential for broader pharmacogenetic testing adoption.
    • Further research and policy development are required to bridge the gap between pharmacogenetic discovery and clinical practice.